|
0
|
| Tweet |
This is an open-label, non-controlled trial in subjects with various pain etiologies at multiple centers in the US. Eligible subjects will include those 22 years of age that have been deemed appropriate for treatment with Provant by the study investigator (prescriber). Subjects will treat based on the treatment prescribed (location, frequency, duration) by the study investigator. Data from assessments administered as part of standard of practice will be obtained at baseline and, at a minimum, at the end of treatment. If the investigator administers additional assessments during the course of treatment, the data will be collected. Safety will be assessed during office visits and through review of AE reports and concomitant treatments and medications. All concomitant drug or non-drug treatments used during the study will be recorded. Information collected in the study will be entered into a registry database.
Enrollment to this protocol will remain open to subjects who participate in current and future protocols with tivozanib. The end of the study is the last treatment visit of the last subject at the last site.
Views: 351
Source: www.clinicaltrials.gov
The duration of administration of tolvaptan will be per medical need as determined by the Principal Investigator. All subjects will be followed for 6 months regardless of the need for treatment.
Views: 326
Source: www.clinicaltrials.gov
This is an open-label, non-controlled trial in subjects with various pain etiologies at multiple centers in the US. Eligible subjects will include those 22 years of age that have been deemed appropriate for treatment with Provant by the study investigator (prescriber).
Views: 315
Source: www.clinicaltrials.gov
Metacognition refers to the awareness of ones knowledge in different areas. The more comprehensive and accurate this metacognitive knowledge, the better one is able to reflect about his or her own actions and behaviors.